plasmaMATCH
A multiple parallel cohort, open-label, multicentre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening.
Disease site: Breast cancer
Treatment modality: Systemic targeted therapy
Status: Closed
Trial details
The UK plasma-based Molecular profiling of Advanced breast cancer to inform Therapeutic Choices (plasmaMATCH) trial is a phase IIa, multiple parallel cohort, open-label, multicentre trial in patients with advanced breast cancer, which aims to assess:
1. Whether analysing a blood sample for circulating tumour DNA (ctDNA) could provide an alternative to biopsies for identifying the genetic mutations present in advanced breast cancer.
2. Whether subgroups of patients with advanced breast cancer, identified through ctDNA screening, may benefit from a treatment targeting their type of cancer.
Approximately 1,150 patients with advanced breast cancer from approximately 20 UK sites will be registered for the trial. Patients will be asked to provide a blood sample for ctDNA screening to test for the presence of several specific, targetable mutations within ctDNA.
Depending on the results of the ctDNA screening, patients will be invited to enter a treatment cohort and receive therapy to target their type of breast cancer. It is expected that ~200 patients will enter into one of five treatment cohorts.
Trial treatment will continue until disease progression occurs, and following treatment discontinuation patients will be followed up for a further two years.
Further information for healthcare professionals
Protocol
Further information
Chief Investigator: Dr Nicholas Turner, The Institute of Cancer Research
ICR-CTSU Scientific Lead: Professor Judith Bliss
Trial management contact: [email protected]
ISRCTN: 16945804
Sponsors: The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
Funding: Cancer Research UK (CRUK/15/010), with additional support from AstraZeneca and Puma Biotechnology
View plasmaMATCH on the National Institute for Health Research website: NIHR - Be Part Of Research
A link to a lay summary in plain English will be added once available.
Publications and presentations
Publications list
Lay summary
Patient infographic to go with summary
This research was funded by the Stand Up to Cancer campaign for Cancer Research UK. 